Cancer
Conditions
Interventions
Standard of care manual ruler based KS lesion assessment
SkinScan3D SS3D AI assisted 2D 3D KS lesion imaging and measurement
Sponsors
Washington University in Saint Louis
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 18 years and above Histopathology-based diagnosis of Kaposi Sarcoma (KS) At least three skin lesions Capable of providing informed consent On treatment for KS (chemotherapy and/or antiretroviral therapy) Patients: histopathology-based KS diagnosis, at least three skin lesions, age 18 years and above, capable of informed consent, and initiating treatment for KS (chemotherapy and/or antiretroviral therapy) Providers: oncologists, medical officers, and nurses involved in delivering KS treatment Administrators: administrators involved in delivering KS treatment
Exclusion criteria
Exclusion criteria: Patients not initiating KS treatment Patients who are very ill / acutely ill and requiring hospitalization Patients, providers, or administrators not willing to participate Patients currently not receiving any treatment for KS Patients who are acutely ill and requiring hospitalization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reproducibility of KS lesion size measurements (CCC), measured at the Aim 1 study assessment visit. Accuracy/agreement of KS lesion size measurements (R-squared; Bland-Altman agreement metrics), measured at the Aim 1 study assessment visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Usability (SUS), acceptability (AIM), appropriateness (IAM), and feasibility (FIM) of SkinScan3D, measured at the end of Aim 2 implementation. Workflow/time-and-motion outcomes, measured during Aim 2 implementation. Implementation/programmatic costs of SS3D versus standard of care, measured during and at the end of Aim 2 implementation. Exploratory correlation of lesion area with lesion height and color, assessed in Aim 1. | — |
Countries
Kenya
Contacts
Public ContactThomas Odeny
Principal Investigator
Outcome results
None listed